NCI vs ELAB
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 02, 2026
NCI
ELAB
Investment Advisor Scores
ELAB
AI Analyst Insights
Detailed Metrics Comparison
| Metric | NCI | ELAB | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 0 | Tie |
| PEG Ratio | 1.13 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -50.8% | -45.8% | ELAB |
| Earnings Growth | 34.0% | 0.0% | NCI |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 48.4/100 | 48.7/100 | ELAB |
| Profit Margin | 0.2% | 0.0% | NCI |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
NCI
MarkupPrice above SMA50, rising 50-day trend (61.0% over 20 days), RSI 71
ELAB
MarkdownPrice below a falling SMA50 (slope -27.2%), weak momentum, RSI 35
Fundamentals Snapshot
| Metric | NCI | ELAB |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 0.0 | 0.0 |
| Trailing P/E | 150.8 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.5% | -0.5% |
| Gross Margin | 0.4% | -0.6% |
| Operating Margin | 0.0% | -4.8% |
| EPS | 0.08 | -161.78 |
| Dividend Yield | — | — |